Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT05956379Enrolling by invitation
Exercise and monitoring study for chronic hepatitis B with fatty liver
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
Taipei, Zhongzheng Dist.Ages 18–70 - NCT06908785Recruiting
Blood test to predict bleeding risk after procedures in cirrhosis
This trial is testing if a special blood test called ROTEM can help doctors predict the risk of bleeding after high-risk procedures in people with cirrhosis. It aims to improve safety and guide treatment decisions.
Santander, CantabriaAges 18–65 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT06968234Recruiting
Liver disease breath test study
This study uses a special breath test to learn about chronic liver disease. If you have liver disease or cirrhosis, you may be able to help by providing a breath sample.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07472049Recruiting
Imaging plaque activity in peripheral artery disease
This trial studies plaque activity in leg arteries using a new imaging method to understand artery disease better. It may help people with peripheral artery disease get more targeted treatment.
Edinburgh, MidlothianAges 18 years+ - NCT05325099RecruitingPhase 1/Phase 2
Azacitidine to help prevent kidney injury after heart surgery
This early-phase study tests whether azacitidine (a medication that changes how cells read genes) can lower the risk of acute kidney injury after cardiac surgery, especially in people already at risk along the chronic kidney disease (CKD) pathway. It aims to protect kidney function during the vulnerable period after surgery.
TaipeiAges 20 years+ - NCT05213598Recruiting
Biomarker study for liver disease after Fontan surgery
This study looks for blood and/or test markers that can better show how severe liver disease is in people who had the Fontan heart procedure. It also involves medical imaging and/or a liver biopsy or related procedures to help evaluate those markers.
Bethesda, MarylandAges 18–100 - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Birmingham, AlabamaAges 18 years+ - NCT06567990Recruiting
Type 2 diabetes and fatty liver: new tests for disease tracking
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
DijonAges 40–80 - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT05780190RecruitingPhase 4
CABA treatment for end-stage liver disease with inflammation
This study tests a treatment called CABA for people with advanced liver disease and inflammation. It aims to see if CABA can help improve liver function and reduce inflammation.
Wuhan, HubeiAges 18–70 - NCT05439226Recruiting
Diet plan targeting liver fat for type 2 diabetes
This study tests whether a Chinese medical nutrition therapy diet can reduce liver fat and help manage type 2 diabetes in people who also have fatty liver. You may be asked to follow a specific eating plan and keep your diabetes care stable during the study.
Yichang, HubeiAges 18–75 - NCT07683065Recruiting
Secukinumab treatment in psoriasis patients with liver condition
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Badalona, BarcelonaAges 18–100 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07662902Enrolling by invitation
Gut Barrier Study in Ulcerative Colitis Remission
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
ZagrebAges 18–70 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07527910RecruitingPhase 2
Study of ALN-PNP with or without tirzepatide for fatty liver disease
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Tucson, ArizonaAges 18–75 - NCT07459504RecruitingPhase 2
Smart diets for kids with fatty liver disease
This study compares different diet plans to see which works best to reduce fat in the liver of children and teens with MASLD (a type of fatty liver disease). If your child drinks sugary beverages often and has certain health risks like being overweight or having high cholesterol, this trial may help find a healthy eating plan that works.
Grand Rapids, MichiganAges 11–17
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 196 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.